Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit

Two year metabolic outcomes in the Association of British Clinical Diabetologist (ABCD) Nationwide Canagliflozin Audit: a comparison of glycaemic improvements

Dr A Puttanna^*1, Dr M Yadagiri¹, Dr P Sen Gupta¹, Dr IW Gallen², Dr A Bickerton³, Dr S Phillips⁴, Dr A Evans⁴, Dr D Sennik⁵, Dr REJ Ryder¹, ABCD nationwide canagliflozin audit contributors⁶

¹Diabetes and Endocrinology, Sandwell and West Birmingham NHS Trust, Birmingham, UK

2 year metabolic outcomes in the ABCD nationwide canagliflozin audit Author Block:

A. Puttanna¹, M. Yadagiri¹, P. Sen Gupta¹, I. Gallen², A. Bickerton³, S. Phillips⁴, A. Evans⁴, D. Sennik⁵, R. Ryder¹

¹Diabetes and Endocrinology, Sandwell and West Birmingham NHS Trust, Birmingham, UK

²Diabetes and Endocrinology, Royal Berkshire Hospitals NHS Trust, Berkshire, UK

Relationship Between Canagliflozin Treatment Response and Duration of Diabetes: The Association of British Clinical Diabetologists (ABCD) Nationwide Canagliflozin Audit

Two year metabolic outcomes in the Association of British Clinical Diabetologist (ABCD) Nationwide Canagliflozin Audit: a comparison of glycaemic improvements

A Puttanna¹, M Yadagiri¹, P Sen Gupta¹, I W Gallen², A Bickerton³, S Phillips⁴, A Evans⁴ , D Sennik⁵, R E J Ryder¹ and ABCD nationwide canagliflozin audit contributors⁶

Two year metabolic outcomes in the Association of British Clinical Diabetologist (ABCD) Nationwide Canagliflozin Audit

A Puttanna¹, M Yadagiri¹, P Sen Gupta¹, I W Gallen², A Bickerton³, S Phillips⁴, A Evans⁴, D Sennik⁵, R E J Ryder¹ and ABCD nationwide canagliflozin audit contributors⁶

¹Sandwell and West Birmingham NHS Trust, Birmingham, UK

²Royal Berkshire Hospitals NHS Trust, Berkshire, UK

One year metabolic outcomes in the Association of British Clinical Diabetologist (ABCD) Nationwide Canagliflozin Audit

M Yadagiri¹, A Robinson², K Darzy³, P Winocour³, A Strzelecka⁴, I W Gallen⁵, A Bickerton⁶, A Evans⁷, R E J Ryder¹ and ABCD nationwide canagliflozin audit contributors⁸

¹Sandwell and West Birmingham NHS Trust, Birmingham, UK

²Royal United Hospital, Bath, UK

The Foundation for the Development of Internal Medicine in Europe (FDIME) is offering Research Grants to Young Internists (up to age 38 yrs) to study in research projects including all fields of General Internal Medicine, particularly polymorbidity and other common I.M. conditions.

Up to 17,500 Euros is available, to be awarded for a maximum study period of 1 year. Deadline for Receipt of Applications is 15 July 2020.

People with type 1 diabetes who are taking SGLT-2 inhibitors (Dapagliflozin, Empagliflozin, Canagliflozin and Ertugliflozin) are at risk of developing diabetic ketoacidosis during any illness. During the Coronavirus epidemic there are some additional safety considerations in treating DKA in patients with COVID-19. In the absence of high quality evidence to guide us, ABCD believes that clinicians may wish to discuss these medications with their patients and possibly mutually agree to stop SGLT-2 inhibitors and control blood glucose by adjusting insulin doses.

We are currently seeking applications for two new ABCD committee members.

All members of ABCD are eligible for application and should be proposed and seconded by other current members of ABCD.

To apply simply complete the online form, the closing date is Wednesday 3rd June 2020.